化学
检出限
蛋白质检测
生物标志物
仪表(计算机编程)
人血浆
临床诊断
信号(编程语言)
多路复用
纳米技术
生物传感器
色谱法
试剂
分子诊断学
滚动圆复制
复矩阵
生物标志物发现
靶蛋白
定量蛋白质组学
循环肿瘤细胞
放大器
计算生物学
作者
Karan Malhotra,Louise L. Hansen,Samuel Han,Shira Roth,David R. Walt
摘要
., plasma or urine) can enable detection of diseases and transform clinical diagnostics and treatment. Digital protein detection assays, such as Single Molecule Arrays (Simoa) and Molecular On-bead Signal Amplification for Individual Counting (MOSAIC), enable ultrasensitive protein quantification, achieving detection limits that are at least 1000-fold lower than those of conventional ELISA assays. Currently, these ultrasensitive assays are performed in centralized laboratories that have access to specialized instrumentation and stable supply chains, which are rarely available in low- and middle-income countries (LMIC) or at the point-of-care (POC) in resource-limited settings. To address the need for ultrasensitive, accessible diagnostic assays, we have developed an enzyme-free platform for the detection of protein biomarkers with simple assay workflows. This approach uses enzyme-free signal amplifiers generated using hybridization chain reaction to achieve detection limits comparable to Simoa for most proteins. The signal amplifier reagent retains full performance when stored in the dark at 21 °C for up to six months. To investigate the utility of efMOSAIC for clinical workflows, we validated the platform for the sensitive detection of cytokines from human plasma and demonstrated multiplexed biomarker detection. With simple assay workflows and temperature stable reagents, efMOSAIC is poised to transform ultrasensitive protein assays making these technologies more accessible for use in LMICs.
科研通智能强力驱动
Strongly Powered by AbleSci AI